American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

NEKTAR THERAPEUTICS (NKTR)

$37.22 -3.70% NASDAQ: NKTR · 15-min delayed

SAN FRANCISCO, California
Public · NASDAQ: NKTR
63 employees
Founded 1990

Visit website Follow

$2.4BMarket cap

$55.2MRevenue · FY2025

-$164.1MNet income

63Employees

NKTRNASDAQ

1994IPO

About NEKTAR THERAPEUTICS

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 1990
Type: Public · NASDAQ: NKTR
Employees: 63
IPO date: May 3, 1994
Headquarters: 455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, California 94158
Phone: (415) 482-5300
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: 5299005I24806IOIYE03

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: NKTR Nasdaq
SEC CIK: 906709
LEI: 5299005I24806IOIYE03
EIN: 943134940
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Nektar Therapeutics’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/nektar-therapeutics/"><img src="https://americancompanies.com/badge/nektar-therapeutics.svg" alt="Nektar Therapeutics — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow NEKTAR THERAPEUTICS and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $55.2M
Net income: -$164.1M
Total assets: $280.4M
Market cap: $2.4B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: NKTR

$37.22 -3.70%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$35.12 $100.35

52-week range

Market cap: $2.4B
Shares outstanding: 64.2M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: May 3, 1994

Nektar Therapeutics (NKTR) Stock Price

Reported a net loss of $164.1M in FY2025.
Trading 63% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review NEKTAR THERAPEUTICS.

Write a review

Newsroom

News about NEKTAR THERAPEUTICS

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? Zacks Investment Research · 2026-10-15 · neutral What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch The Motley Fool · 2026-05-23 · positive Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm GlobeNewswire Inc. · 2026-05-05 · negative NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Enrollment Protocol Compliance: Levi & Korsinsky GlobeNewswire Inc. · 2026-05-05 · negative NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th GlobeNewswire Inc. · 2026-05-04 · negative NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR GlobeNewswire Inc. · 2026-05-04 · negative

News & sentiment via Polygon.io

FAQ

Nektar Therapeutics: frequently asked questions

Is Nektar Therapeutics an American company?

Nektar Therapeutics is a US-based company headquartered in San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Nektar Therapeutics headquartered?

Nektar Therapeutics is headquartered in San Francisco, California, United States.

Is Nektar Therapeutics publicly traded?

Yes — Nektar Therapeutics is a publicly traded company. Its stock trades under the ticker symbol NKTR on the NASDAQ.

What does Nektar Therapeutics do?

Nektar Therapeutics is an American Pharmaceuticals company in the Health & Beauty sector.

When was Nektar Therapeutics founded?

Nektar Therapeutics was founded in 1990.

Explore